Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer

OBJECTIVES: A small subset of patients treated with immune checkpoint inhibitors manifest atypical patterns of response, the so-called pseudoprogression (PP) and hyperprogression (HP). Their prevalence in urothelial (UC) and renal cancer (RCC) remains, to date, mostly uninvestigated. Therefore, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria, Francesco, Beleni, Andrea I., D’Andrea, David, Resch, Irene, Gust, Kilian M., Gontero, Paolo, Shariat, Shahrokh F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208670/
https://www.ncbi.nlm.nih.gov/pubmed/29549485
http://dx.doi.org/10.1007/s00345-018-2264-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208670/
https://www.ncbi.nlm.nih.gov/pubmed/29549485
http://dx.doi.org/10.1007/s00345-018-2264-0

Ejemplares similares